Showing results (81-90 of 34,619) with videos related to
Sort By:
Pageof 3,462
Cancer|October 15, 2010
Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomyMin Yi, Steven J Kronowitz, Funda Meric-Bernstam, et al.Cancer|October 15, 2010
Concordance in histological and biological parameters between first and second primary breast cancersDezheng Huo, Stephanie Melkonian, Paul J Rathouz, et al.Cancer|October 15, 2010
Trends in survival for patients with metastatic soft-tissue sarcomaAntoine Italiano, Simone Mathoulin-Pelissier, Axel Le Cesne, et al.Cancer|October 21, 2010
The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecanPeter E Zage, Timothy C Graham, Lizhi Zeng, et al.Cancer|October 21, 2010
Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosisMario W Kramer, Diogo O Escudero, Soum D Lokeshwar, et al.Cancer|October 21, 2010
Monitoring molecular response in chronic myeloid leukemiaJorge Cortes, Alfonso Quintás-Cardama, Hagop M KantarjianCancer|October 21, 2010
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphomaAntonino Musolino, Daniela Boggiani, Michele Panebianco, et al.Cancer|December 21, 2010
Stage of breast cancer at diagnosis among low-income women with access to mammographyRebecca Lobb, John Z Ayanian, Jennifer D Allen, et al.Cancer|February 18, 2011
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progressionJatin Shah, Joan Bladé, Pieter Sonneveld, et al.Pageof 3,462